Inside the research

Neogen Corporation

NEOG Research profile · latest available data

Price overview

$13.76

▲ +0.10 (+0.7%)

52w hi$13.98
52w lo$5.36
Vol5.22M
As of25 Sep 2026

The Verdict

Strong Buy

Our score +2.07

Short+4.21
Medium+1.13
Long-0.31

computed 2026-09-27

Key fundamentals

Neogen Corporation

Healthcare · Medical Devices

Market cap$3.00B
Enterprise value$3.63B
Forward P/E36.21x
EV / EBITDA38.31x
P / S (ttm)3.45x
Profit margin-0.9%
Return on equity-0.4%
Revenue growth-0.1%
Debt / equity38.83

Layer Breakdown

LayerRawContribution
Fundamental-0.04
Sector+0.08
Technical+0.26
Earnings+0.49
Sentiment+0.53

macro × 1.00 · 2026-09-27

Business overview

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

United States · www.neogen.com

Risk Metrics

Beta vs SPX0.41
Corr SPX0.11
Annual vol61.8%
Annual ret+7.1%
Sharpe0.12
Max DD-74.8%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-07Officer / Director Changeread
2026-07-30Earnings Release, Exhibitsread
2026-04-20Reg FD Disclosure, Exhibitsread
2026-04-09Earnings Release, Exhibitsread
2026-03-30Officer / Director Changeread
2026-01-08Earnings Release, Exhibitsread
2025-10-30Officer / Director Change, Other Material Event…read
2025-10-27Shareholder Vote, Exhibitsread
2025-10-09Earnings Release, Exhibitsread
2025-09-15Officer / Director Change, Other Material Event…read
2025-08-21Officer / Director Change, Exhibitsread
2025-08-14Officer / Director Change, Other Material Event…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-14Moylan John PatrickChief Accounting OfficerGrant8.58K$100.00K
2026-08-14Ranalli Tamara A.Senior Vice PresidentGrant25.75K$300.00K
2026-08-14Stacey Jennifer EvansChief Legal OfficerGrant38.63K$450.00K
2026-08-14Riggsbee Richard BryanCFOGrant51.50K$600.00K
2026-08-14Nassif MikhealCEOGrant141.63K$1.65M
2026-08-04Nassif MikhealCEOBuy370$4.37K
2026-06-03Moylan John PatrickChief Accounting OfficerWithheld for tax2.55K$22.34K
2026-05-18Rocklin Amy MFormer Chief Legal OfficeOption exercise35.18K$326.85K
2026-05-18Rocklin Amy MFormer Chief Legal OfficeWithheld for tax10.24K$95.14K
2026-05-04Moylan John PatrickChief Accounting OfficerOption exercise4.56K$43.44K

Flow & Concentration

Insider 180d net$4.37K
Insider buys / sells1 / 0
Insider biasNeutral
13F holders7
Top-5 share99.1%
HHI4,951 (concentrated)

Top Holders

HolderValueShares
State Street Corp$80.43M8.95M
Capital Research / Capital World$15.08M1.68M
Fidelity / FMR LLC$10.48M1.17M
Citadel Advisors$6.22M691.83K
AQR Capital Management$4.49M500.36K
Renaissance Technologies$1.06M118.24K
T. Rowe Price Group$2.71K301.36K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-078-Kview
2026-08-064view
2026-07-3010-Kview
2026-07-308-Kview
2026-06-2511-Kview
2026-06-044view
2026-05-194view
2026-05-054view
2026-05-044view
2026-04-208-Kview

The Long Run

FY 2012–2025 · 14 years

LineLatestCAGRTrend
Revenue$924.22M+26.4%
Gross profit$421.38M+12.4%
Operating income$37.52M+0.8%
Net income-$1.09B+7.9%
Cash from ops$35.26M+4.7%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$13.68$13.86$13.38$13.765.22M
Sep 24$13.48$14.01$13.46$13.663.83M
Sep 23$14.21$14.26$13.50$13.573.68M
Sep 22$13.62$14.18$13.61$13.984.62M
Sep 21$13.12$13.72$12.96$13.614.40M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →